1. All‐cause and cardiorenal mortality in 6 million adults with and without type 2 diabetes: A comparative, trend analysis in Canada, Spain, and the UK. Issue 1 (26th September 2022) Authors: Ling, Suping; Zaccardi, Francesco; Vlacho, Bogdan; Li, Ping; Real Gatius, Jordi; Mata‐Cases, Manel; Franch‐Nadal, Josep; Kosiborod, Mikhail N.; Gillies, Clare; Fenici, Peter; Mauricio, Dídac; Shah, Baiju R.; Khunti, Kamlesh Journal: Diabetes, obesity & metabolism Issue: Volume 25:Issue 1(2023) Page Start: 132 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Assessing the cost‐effectiveness of sodium–glucose cotransporter‐2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real‐world evidence. Issue 12 (2nd September 2020) Authors: McEwan, Phil; Bennett, Hayley; Khunti, Kamlesh; Wilding, John; Edmonds, Christopher; Thuresson, Marcus; Wittbrodt, Eric; Fenici, Peter; Kosiborod, Mikhail Journal: Diabetes, obesity & metabolism Issue: Volume 22:Issue 12(2020) Page Start: 2364 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Association of sodium‐glucose cotransporter‐2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD‐REAL 2 study. Issue 6 (23rd March 2021) Authors: Lam, Carolyn S. P.; Karasik, Avraham; Melzer‐Cohen, Cheli; Cavender, Matthew A.; Kohsaka, Shun; Norhammar, Anna; Thuresson, Marcus; Chen, Hungta; Wittbrodt, Eric; Fenici, Peter; Kosiborod, Mikhail Journal: Diabetes, obesity & metabolism Issue: Volume 23:Issue 6(2021) Page Start: 1431 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Burden of cardio‐renal‐metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry. Issue 8 (19th April 2018) Authors: Arnold, Suzanne V.; Kosiborod, Mikhail; Wang, Jingyan; Fenici, Peter; Gannedahl, Goran; LoCasale, Robert J. Journal: Diabetes, obesity & metabolism Issue: Volume 20:Issue 8(2018) Page Start: 2000 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Issue 9 (September 2017) Authors: Birkeland, Kåre I; Jørgensen, Marit E; Carstensen, Bendix; Persson, Frederik; Gulseth, Hanne L; Thuresson, Marcus; Fenici, Peter; Nathanson, David; Nyström, Thomas; Eriksson, Jan W; Bodegård, Johan; Norhammar, Anna Journal: Lancet Issue: Volume 5:Issue 9(2017) Page Start: 709 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Cardiovascular protection with sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: Does it apply to all patients?. Issue 9 (7th May 2020) Authors: Giorgino, Francesco; Vora, Jiten; Fenici, Peter; Solini, Anna Journal: Diabetes, obesity & metabolism Issue: Volume 22:Issue 9(2020) Page Start: 1481 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study. Issue 2 (8th September 2017) Authors: Persson, Frederik; Nyström, Thomas; Jørgensen, Marit E.; Carstensen, Bendix; Gulseth, Hanne L.; Thuresson, Marcus; Fenici, Peter; Nathanson, David; Eriksson, Jan W.; Norhammar, Anna; Bodegard, Johan; Birkeland, Kåre I. Journal: Diabetes, obesity & metabolism Issue: Volume 20:Issue 2(2018) Page Start: 344 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Durability of glycaemic control in patients with type 2 diabetes after metformin failure: Prognostic model derivation and validation using the DISCOVER study. Issue 5 (21st February 2020) Authors: Ling, Suping; Sun, Ping; Zaccardi, Francesco; Khosla, Sajan; Cooper, Andrew; Fenici, Peter; Khunti, Kamlesh Journal: Diabetes, obesity & metabolism Issue: Volume 22:Issue 5(2020) Page Start: 828 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study. Issue 1 (21st March 2019) Authors: Pintat, Stéphane; Fenici, Peter; Hammar, Niklas; Ji, Linong; Khunti, Kamlesh; Medina, Jesús; Tang, Fengming; Wittbrodt, Eric; Surmont, Filip Journal: BMJ open diabetes research and care Issue: Volume 7:Issue 1(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the DISCOVER study. Issue 1 (22nd September 2020) Authors: Patel, Krishna K.; Gomes, Marilia B.; Charbonnel, Bernard; Chen, Hungta; Cid‐Ruzafa, Javier; Fenici, Peter; Hammar, Niklas; Ji, Linong; Kennedy, Kevin F.; Khunti, Kamlesh; Kosiborod, Mikhail; Pocock, Stuart; Shestakova, Marina V.; Shimomura, Iichiro; Surmont, Filip; Watada, Hirotaka; Arnold, Suza... Journal: Diabetes, obesity & metabolism Issue: Volume 23:Issue 1(2021) Page Start: 39 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗